Philippe Barthélémy

机构：Centre National de la Recherche Scientifique, Université de Bordeaux, Inserm, Institut de Cancérologie Strasbourg, Bordeaux Population Health, Hôpitaux Universitaires de Strasbourg, Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Civil, Strasbourg, Acides nucléiques: Régulations naturelles et artificielles, Université de Strasbourg · ORCID：0009-0006-3868-186X

发表论文 261 篇 · 总被引 5235 次 · h-index 32

代表论文

• rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC (2025 · Future Oncology · 被引 12)
• Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study (2025 · European Journal of Cancer · 被引 8)
• Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 4)
• A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge). (2025 · Journal of Clinical Oncology · 被引 4)
• Beyond the Scalpel: the Role of Image-Guided Thermal Ablation in Management of Metastatic Renal Cell Carcinoma in the Era of Immunotherapy (2025 · CardioVascular and Interventional Radiology · 被引 2)
• Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study (2025 · Clinical Genitourinary Cancer · 被引 1)